Alnylam Pharmaceuticals, Inc. vs Wayfair Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.42 (market cap $29.60B), while Wayfair Inc trades at $103.54 (market cap $14.14B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.1× Wayfair Inc's market cap, and Wayfair Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | W | |
|---|---|---|
Market Cap | $29.60B | $14.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $119.05 |
52-Week Low | $205.48 | $57.40 |
Enterprise Value | $27.56B | $16.47B |
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Wayfair (W) trades at $103.59, up 0.25% with bullish technical signals including a golden cross pattern. The company reported strong Q2 2026 results with EPS of $0.95 beating estimates and 7.5% revenue growth. Despite negative net margins, operating cash flow improved to $534 million in 2025. Analyst consensus leans bullish with 52% buy ratings and a $122 price target representing 18% upside potential.
The outlook remains positive driven by U.S. market share gains and margin expansion guidance, though risks include persistent losses and high debt levels. Technical support at $102 provides near-term protection while resistance at $105-108 marks the next challenge. The stock's momentum appears sustainable if execution continues.
Trailing returns across standard periods
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →